RU94003148A - Method of treating malignant neoplasms of epithelial origin - Google Patents

Method of treating malignant neoplasms of epithelial origin

Info

Publication number
RU94003148A
RU94003148A RU94003148/14A RU94003148A RU94003148A RU 94003148 A RU94003148 A RU 94003148A RU 94003148/14 A RU94003148/14 A RU 94003148/14A RU 94003148 A RU94003148 A RU 94003148A RU 94003148 A RU94003148 A RU 94003148A
Authority
RU
Russia
Prior art keywords
treatment
days
malignant neoplasms
epithelial origin
delta
Prior art date
Application number
RU94003148/14A
Other languages
Russian (ru)
Other versions
RU2106866C1 (en
Inventor
Л.К. Каменек
А.Ф. Лазарев
Original Assignee
Л.К. Каменек
А.Ф. Лазарев
Filing date
Publication date
Application filed by Л.К. Каменек, А.Ф. Лазарев filed Critical Л.К. Каменек
Priority to RU94003148A priority Critical patent/RU2106866C1/en
Priority claimed from RU94003148A external-priority patent/RU2106866C1/en
Publication of RU94003148A publication Critical patent/RU94003148A/en
Application granted granted Critical
Publication of RU2106866C1 publication Critical patent/RU2106866C1/en

Links

Claims (1)

Способ относится к медицине, а именно к лечению злокачественных новообразований эпителиального происхождения. Способ включает ежедневное однократное введение противоопухолевого биологического препарата в течение всего курса лечения. Новым в способе является использование в качестве противоопухолевого биологического препарата, предварительно разложенного до полипептидов дельта-эндотоксина, являющегося продуктом жизнедеятельности Bacillus thuringiensis, разовая доза которого составляет 30 - 80 мг, суммарная - 700 - 2800 мг, а общая продолжительность лечения - 20 - 60 дней, причем лечение может осуществляться отдельными курсами длительностью 20 - 30 дней с перерывом между ними в 20 - 60 дней. В варианте препарат может содержать питьевую соду в количестве 100 - 150 мг на 1 мг дельта-эндотоксина, или может запиваться водным раствором питьевой соды в тех же соотношениях к количеству препарата. Таким образом, использование предлагаемого способа позволяет обеспечить достижение лечебного эффекта и исключить нежелательные побочные явления.The method relates to medicine, namely to the treatment of malignant neoplasms of epithelial origin. The method includes daily single injection of an anticancer biological drug during the entire course of treatment. New in the method is the use as an anticancer biological drug, previously decomposed to the delta-endotoxin polypeptides, which is the product of Bacillus thuringiensis, a single dose of 30 - 80 mg, total - 700 - 2800 mg, and the total duration of treatment - 20 - 60 days , and treatment can be carried out by separate courses lasting 20 - 30 days with a break between them in 20 - 60 days. In a variant, the preparation may contain baking soda in the amount of 100-150 mg per 1 mg of delta-endotoxin, or it may be washed down with an aqueous solution of baking soda in the same ratios to the amount of the preparation. Thus, the use of the proposed method allows to achieve a therapeutic effect and eliminate unwanted side effects.
RU94003148A 1994-01-28 1994-01-28 Method for treating malignant neoplasms of epithelium origin RU2106866C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU94003148A RU2106866C1 (en) 1994-01-28 1994-01-28 Method for treating malignant neoplasms of epithelium origin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU94003148A RU2106866C1 (en) 1994-01-28 1994-01-28 Method for treating malignant neoplasms of epithelium origin

Publications (2)

Publication Number Publication Date
RU94003148A true RU94003148A (en) 1995-12-27
RU2106866C1 RU2106866C1 (en) 1998-03-20

Family

ID=20151891

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94003148A RU2106866C1 (en) 1994-01-28 1994-01-28 Method for treating malignant neoplasms of epithelium origin

Country Status (1)

Country Link
RU (1) RU2106866C1 (en)

Similar Documents

Publication Publication Date Title
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
CA2189658A1 (en) Controlled-Release Dosage Forms of Azithromycin
PL338982A1 (en) Drug for improving duration of muscle action or for treating muscular disorders or diseases
GEP20002032B (en) (54) Pyrido[2,3-d]Pyrimidines and Pharmaceutically Acceptable Salts Thereof, Pharmaceutical Composition Comprising Them and Methods of Treatment
RU2002116361A (en) ANALGESIC COMPOSITIONS CONTAINING BUPRENORPHIN
MY131810A (en) Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
RU94027680A (en) Parathyroid hormone and raloxifen for bone mass increase, pharmaceutical composition and method of osseous mass increase
CA2186673A1 (en) The use of fatty acids in the treatment of huntington's chorea
CA2286671A1 (en) Method and formulation for treating vascular disease
MXPA03010402A (en) 4-amino-5-phenyl-7-cyclobutyl-pyrrolo (2,3-d) pyrimidine derivatives.
CA2314326A1 (en) Transdermal therapeutic device and method with capsaicin and capsaicin analogs
SE9401406D0 (en) Pharmaceutical products for curing tumourous diseases and process for preparing same
BR9813318A (en) Process of treating tumors and macular degeneration in a human or veterinary patient, pharmaceutical composition for treating tumors and macular degeneration in a human or veterinary patient
PT1237562E (en) PROCESS OF PREPARATION OF MYCANYAN EXTRACTS CONTAINING MICANOLIDE AND DIHYDROMICANOLID AND USES IN THE TREATMENT OF PROLIFERATIVE DISEASES
DE69939075D1 (en) Pharmaceutical composition for the prevention and treatment of diseases associated with cell diseases of the fundus
CA2319542A1 (en) The treatment of sexual dysfunction in certain patient groups
RU94003148A (en) Method of treating malignant neoplasms of epithelial origin
PT1007085E (en) USES OF GROWTH HORMONE IN COMPOSITIONS FOR THE TREATMENT OF INSULIN RESISTANCE IN THE HEART
KR960003741A (en) Osteoblast proliferation factor
RU2004103531A (en) PHARMACEUTICAL COMPOSITION FOR ORAL USE CONTAINING SIMULTANEOUS METFORMIN AND GLYCLAZIDE
RU96117561A (en) METHOD OF TREATING TOXICOMANIA
RU97106986A (en) MEANS AND METHOD FOR TREATING ISCHEMIC STROKE
RU95121400A (en) METHOD FOR TREATMENT OF RECURRENT SINUITES WITH APPLICATION OF BACTERICID-FUNGICID DEPOT DRUG
RU94013606A (en) Hemostimulator
RU95113855A (en) METHOD FOR CONSERVATIVE TREATMENT OF EYE BURNS